


HPLC Method for Analysis of Fitusiran on OligoMG Column



Separation type: Bridge Ion Separation Technology, or BIST™ by SIELC Technologies

Fitusiran is a relatively new therapeutic agent developed for the treatment of hemophilia A and B , including in patients with or without inhibitors.

Using SIELC's newly introduced BIST™ method, this oligonucleotide can be retained on a OligoMg column. Using this new and unique analysis method, oligonucleotide can be separated, retained, and detected at 260 nm.

Please read more on oligonucleotides analysis by HPLC in our June 2024 newsletter .

Method Parameters

Column	OligoMg, 4.6 x 100 mm, 3 µm, 100 Å, dual ended
Mobile Phase	Gradient MeCN60-10%, 10 min
Buffer	none
Flow Rate	1.0 mL/min
Detection	UV 260 nm

Quelle: <https://sielc.com/hplc-method-fitusiran>